Global RNAi Drug Pipeline Analysis 2013 Market Report ReportsnReports.com adds Global RNAi Drug Pipeline Analysis 2013 market research report by PNS Pharma to its store. The research gives comprehensive insight on the various drugs being developed based upon RNAi technology
DALLAS, Oct. 23, 2013 PRNewswire-iReach/ -- Global RNAi Drug Pipeline Analysis 2013 market research report covers all the ongoing drugs being developed in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the RNAi technology associated with the various diseases.
This report (http://www.reportsnreports.com/reports/269587-global-rnai-drug-pipeline-analysis.html ) enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the RNAi Drug market based upon development process.
Following parameters for each drug profile in development phase are covered in "Global RNAi Drug Pipeline Analysis" research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Orphan Designation by Indication, Country & Organisation
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
Breakup of RNAi Drug by Development Phase:
- Research: 26
- Phase-I: 88
- Phase-I/II: 5
- Phase-II: 10
- Phase-III: 1
Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=269587 .
Other newly published reports by PNS Pharma available with ReportsnReports.com:
US Orphan Drug Pipeline Analysis is available at http://www.reportsnreports.com/reports/269585-us-orphan-drug-pipeline-analysis.html : In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections..
Europe Orphan Drugs Pipeline Analysis is available at http://www.reportsnreports.com/reports/269586-europe-orphan-drugs-pipeline-analysis.html : This report gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug pr...
Orphan Drugs for Cancer Pipeline Analysis is available at http://www.reportsnreports.com/reports/269589-orphan-drugs-for-cancer-pipeline-analysis.html : A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority...
Global Oncolytic Virus Therapy Pipeline Analysis is available at http://www.reportsnreports.com/reports/269588-global-oncolytic-virus-therapy-pipeline-analysis.html : Though still in nascent stages, Oncolytic viruses have shown immense opportunities and potential to be tapped in the future to improve the treatment of cancer and the lives of the patients. Immunotherapy, the umbrella for Oncolytic viruses would n...
Table of Contents for Global RNAi Drug Pipeline Analysis 2013 market research report include:
1. Global RNAi Drug Market Outlook
1.1 Current Market Scenario
1.2 Key Drivers for Adopting RNAi
1.3 Future Opportunity
2. RNAi Drug Development Phase: Research
2.2 RNAi Drug Profile in Development Phase
3. RNAi Drug Development Phase: Preclinical
3.2 RNAi Drug Profile in Development Phase
4. RNAi Drug Development Phase: Phase-I
4.2 RNAi Drug Profile in Development Phase
5. RNAI Drug Development Phase: Phase:I/II
5.2 RNAi Drug Profile in Development Phase
6. RNAi Drug Development Phase: Phase-II
6.2 RNAi Drug Profile in Development Phase
7. RNAi Drug Development Phase: Phase-III
7.2 RNAi Drug Profile in Development Phase
List of Tables & figures
Each Drug Profile has Tables Representing Following Information:
- Alternate Names
- Originator & Owner
- Technology Provider
- Highest Development Phase
- Mechanism of action
- WHO & EphMRA ATC code
- Allocated Brand Name & orphan Designation
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication. Not limited to the pharmaceutical industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, consumer goods, environment, food and beverages, healthcare, biotechnology, medical devices, water, retail and much more.
Media Contact: Priyank Tiwari, ReportsnReports.com, +1 888 391 5441, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com